Log in

NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Forecast & News

$2.48
+0.08 (+3.33 %)
(As of 03/29/2020 05:03 AM ET)
Today's Range
$2.41
Now: $2.48
$2.60
50-Day Range
$2.20
MA: $2.94
$3.39
52-Week Range
$2.05
Now: $2.48
$8.24
Volume12,735 shs
Average Volume20,451 shs
Market Capitalization$46.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Read More
Alpine Immune Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$700,000.00
Book Value$3.22 per share

Profitability

Net Income$-36,490,000.00

Miscellaneous

Employees48
Market Cap$46.10 million
Next Earnings Date3/30/2020 (Confirmed)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.


Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

How has Alpine Immune Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALPN stock has decreased by 14.8% and is now trading at $2.48. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alpine Immune Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alpine Immune Sciences.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 30th 2020. View our earnings forecast for Alpine Immune Sciences.

How can I listen to Alpine Immune Sciences' earnings call?

Alpine Immune Sciences will be holding an earnings conference call on Monday, March 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) issued its quarterly earnings data on Wednesday, November, 13th. The biotechnology company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.06. The biotechnology company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.38 million. View Alpine Immune Sciences' earnings history.

What price target have analysts set for ALPN?

1 analysts have issued 12 month price objectives for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Alpine Immune Sciences' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 222.6% from the stock's current price. View analysts' price targets for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

Media headlines about ALPN stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAlpine Immune Sciences.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 4,400 shares, a decline of 56.0% from the February 27th total of 10,000 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are short sold. View Alpine Immune Sciences' Current Options Chain.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.69%) and Alpine Woods Capital Investors LLC (0.06%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC. View institutional ownership trends for Alpine Immune Sciences.

Which major investors are selling Alpine Immune Sciences stock?

ALPN stock was sold by a variety of institutional investors in the last quarter, including Alpine Woods Capital Investors LLC. View insider buying and selling activity for Alpine Immune Sciences.

Which major investors are buying Alpine Immune Sciences stock?

ALPN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey, and Mitchell Gold. View insider buying and selling activity for Alpine Immune Sciences.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $2.48.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $46.10 million and generates $700,000.00 in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe. View additional information about Alpine Immune Sciences.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  330 (Thanks for Voting!)
Underperform Votes:  354 (Thanks for Voting!)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel